Matrix metalloproteinases and their multiple roles in Alzheimer's disease

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Wang, Xiang Xiang ^a,b   Tan, Meng Shan ^c   Yu, Jin Tai ^a   Tan, Lan ^a,c  

^a QINGDAO UNIVERSITY   (China)

^b Department of Medicine   (China)

^c OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; GELATINASE; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; OLIGOMER; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; HUMAN; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; BIOLOGICAL MODEL; ENZYMOLOGY; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; HUMANS; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL;

EID: 84904110596     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/908636     Document Type: Review

References (46)

1. Ethell I. M., Ethell D. W., Matrix metalloproteinases in brain development and remodeling: Synaptic functions and targets. Journal of Neuroscience Research 2007 85 13 2813 2823 10.1002/jnr.21273 2-s2.0-34547957954 (Pubitemid 47523564)
2. Mroczko B., Groblewska M., Barcikowska M., The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathophysiology of neurodegeneration: a literature study. Journal of Alzheimer's Disease 2013 37 2 273 283
3. Fujimoto M., Takagi Y., Aoki T., Hayase M., Marumo T., Gomi M., Nishimura M., Kataoka H., Hashimoto N., Nozaki K., Tissue inhibitor of metalloproteinases protect blood-brain barrier disruption in focal cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism 2008 28 10 1674 1685 10.1038/jcbfm.2008.59 2-s2.0-52549107417
4. Haorah J., Ramirez S. H., Schall K., Smith D., Pandya R., Persidsky Y., Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction. Journal of Neurochemistry 2007 101 2 566 576 10.1111/j.1471-4159.2006.04393.x 2-s2.0-34047114464 (Pubitemid 46525283)
5. Sbai O., Ferhat L., Bernard A., Gueye Y., Ould-Yahoui A., Thiolloy S., Charrat E., Charton G., Tremblay E., Risso J., Chauvin J., Arsanto J., Rivera S., Khrestchatisky M., Vesicular trafficking and secretion of matrix metalloproteinases-2, -9 and tissue inhibitor of metalloproteinases-1 in neuronal cells. Molecular and Cellular Neuroscience 2008 39 4 549 568 10.1016/j.mcn.2008.08.004 2-s2.0-56249114089
6. Merlo S., Sortino M. A., Estrogen activates matrix metalloproteinases-2 and -9 to increase beta amyloid degradation. Molecular and Cellular Neuroscience 2012 49 4 423 429 10.1016/j.mcn.2012.02.005 2-s2.0-84858719450
7. Miners J. S., Baig S., Palmer J., Palmer L. E., Kehoe P. G., Love S., A β -degrading enzymes in Alzheimer's disease. Brain Pathology 2008 18 2 240 252 10.1111/j.1750-3639.2008.00132.x 2-s2.0-41149149615 (Pubitemid 351436347)
8. Li W., Poteet E., Xie L., Liu R., Wen Y., Yang S., Regulation of matrix metalloproteinase 2 by oligomeric amyloid β protein. Brain Research 2011 1387 141 148 10.1016/j.brainres.2011.02.078 2-s2.0-79954422020
9. Li X.-H., Lv B.-L., Xie J.-Z., Liu J., Zhou X.-W., Wang J., AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiology of Aging 2012 33 7 1400 1410 10.1016/j.neurobiolaging. 2011.02.003 2-s2.0-84861192034
10. Cho H. J., Son S. M., Jin S. M., Hong H. S., Shin D. H., Kim S. J., Huh K., Mook-Jung I., RAGE regulates BACE1 and A β generation via NFAT1 activation in Alzheimer's disease animal model. The FASEB Journal 2009 23 8 2639 2649 10.1096/fj.08-126383 2-s2.0-68849129707
11. 2+-calcineurin signaling. Journal of Neuroscience 2012 32 26 8845 8854 10.1523/JNEUROSCI.6102-11.2012 2-s2.0-84862885703
12. Du H., Li P., Wang J., Qing X., Li W., The interaction of amyloid b and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells. Cellular and Molecular Neurobiology 2012 32 1 141 147 10.1007/s10571-011-9744-8 2-s2.0-84856543572
13. Haass C., Selkoe D. J., Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β -peptide. Nature Reviews Molecular Cell Biology 2007 8 2 101 112 10.1038/nrm2101 2-s2.0-33847662852 (Pubitemid 46432529)
14. Hashimoto H., Takeuchi T., Komatsu K., Miyazaki K., Sato M., Higashi S., Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of β -amyloid precursor protein-derived inhibitor. The Journal of Biological Chemistry 2011 286 38 33236 33243 10.1074/jbc.M111.264176 2-s2.0-80052993945
15. Crouch P. J., Tew D. J., Du T., Nguyen D. N., Caragounis A., Filiz G., Blake R. E., Trounce I. A., Soon C. P. W., Laughton K., Perez K. A., Li Q., Cherny R. A., Masters C. L., Barnham K. J., White A. R., Restored degradation of the Alzheimer's amyloid- β peptide by targeting amyloid formation. Journal of Neurochemistry 2009 108 5 1198 1207 10.1111/j.1471-4159.2009.05870.x 2-s2.0-59449101792
16. Mizoguchi H., Takuma K., Fukuzaki E., Ibi D., Someya E., Akazawa K., Alkam T., Tsunekawa H., Mouri A., Noda Y., Nabeshima T., Yamada K., Matrix metalloprotease-9 inhibition improves amyloid β -mediated cognitive impairment and neurotoxicity in mice. Journal of Pharmacology and Experimental Therapeutics 2009 331 1 14 22 10.1124/jpet.109.154724 2-s2.0-70349330693
17. Bruno M. A., Mufson E. J., Wuu J., Cuello A. C., Increased matrix metalloproteinase 9 activity in mild cognitive impairment. Journal of Neuropathology and Experimental Neurology 2009 68 12 1309 1318 10.1097/NEN.0b013e3181c22569 2-s2.0-73349089956
18. Lorenzl S., Buerger K., Hampel H., Beal M. F., Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. International Psychogeriatrics 2008 20 1 67 76 10.1017/S1041610207005790 2-s2.0-37149052133 (Pubitemid 350256061)
19. Bjerke M., Zetterberg H., Edman Å., Blennow K., Wallin A., Andreasson U., Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. Journal of Alzheimer's Disease 2011 27 3 665 676 10.3233/JAD-2011-110566 2-s2.0-82555184961
20. Talamagas A. A., Efthimiopoulos S., Tsilibary E. C., Figueiredo-Pereira M. E., Tzinia A. K., Abeta(1-40)-induced secretion of matrix metalloproteinase-9 results in sAPP α release by association with cell surface APP. Neurobiology of Disease 2007 28 3 304 315 10.1016/j.nbd.2007.07.016 2-s2.0-36249015501 (Pubitemid 350123595)
21. Michaluk P., Mikasova L., Groc L., Frischknecht R., Choquet D., Kaczmarek L., Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin β 1 signaling. Journal of Neuroscience 2009 29 18 6007 6012 10.1523/JNEUROSCI.5346-08.2009 2-s2.0-65949118911
22. Guo S., Wang S., Kim W. J., Lee S., Frosch M. P., Bacskai B. J., Greenberg S. M., Lo E. H., Effects of apoE isoforms on beta-amyloid-induced matrix metalloproteinase-9 in rat astrocytes. Brain Research 2006 1111 1 222 226 10.1016/j.brainres.2006.06.041 2-s2.0-33748300970 (Pubitemid 44331175)
23. Bell R. D., Winkler E. A., Singh I., Sagare A. P., Deane R., Wu Z., Holtzman D. M., Betsholtz C., Armulik A., Sallstrom J., Berk B. C., Zlokovic B. V., Apolipoprotein e controls cerebrovascular integrity via cyclophilin A. Nature 2012 485 7399 512 516 10.1038/nature11087 2-s2.0-84861418194
24. Yan P., Hu X., Song H., Yin K., Bateman R. J., Cirrito J. R., Xiao Q., Hsu F. F., Turk J. W., Xu J., Hsu C. Y., Holtzman D. M., Lee J., Matrix metalloproteinase-9 degrades amyloid- β fibrils in vitro and compact plaques in situ. The Journal of Biological Chemistry 2006 281 34 24566 24574 10.1074/jbc.M602440200 2-s2.0-33747680357 (Pubitemid 44274231)
25. Barkus C., McHugh S. B., Sprengel R., Seeburg P. H., Rawlins J. N. P., Bannerman D. M., Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion. European Journal of Pharmacology 2010 626 1 49 56 10.1016/j.ejphar.2009.10.014 2-s2.0-70649109843
26. Koronyo-Hamaoui M., Ko M. K., Koronyo Y., Azoulay D., Seksenyan A., Kunis G., Pham M., Bakhsheshian J., Rogeri P., Black K. L., Farkas D. L., Schwartz M., Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. Journal of Neurochemistry 2009 111 6 1409 1424 10.1111/j.1471-4159.2009.06402.x 2-s2.0-70450215332
27. NTR and sortilin. Journal of Neurochemistry 2008 107 4 1124 1135 10.1111/j.1471-4159.2008.05698.x 2-s2.0-54349117308
28. Costantini C., Weindruch R., Della Valle G., Puglielli L., A TrkA-to- p75 NTR molecular switch activates amyloid β -peptide generation during aging. Biochemical Journal 2005 391, part 1 59 67 10.1042/BJ20050700 2-s2.0-26844507790 (Pubitemid 41445476)
29. Frost B., Jacks R. L., Diamond M. I., Propagation of tau misfolding from the outside to the inside of a cell. The Journal of Biological Chemistry 2009 284 19 12845 12852 10.1074/jbc.M808759200 2-s2.0-67649273927
30. Hernández-Guillamon M., Delgado P., Ortega L., Pares M., Rosell A., García-Bonilla L., Fernández-Cadenas I., Borrell-Pagès M., Boada M., Montaner J., Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by β -amyloid 25-35 fragment. Journal of Neuroscience Research 2009 87 9 2115 2125 10.1002/jnr.22034 2-s2.0-65849506917
31. Mannello F., Medda V., Nuclear localization of Matrix metalloproteinases. Progress in Histochemistry and Cytochemistry 2012 47 1 27 58 10.1016/j.proghi.2011.12.002 2-s2.0-84856234425
32. Nübling G., Levin J., Bader B., Israel L., Bötzel K., Lorenzl S., Giese A., Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation. Experimental Neurology 2012 237 2 470 476 10.1016/j.expneurol.2012.07.018 2-s2.0-84865306278
33. Choi D. H., Kim E., Son H. J., Joh T. H., Kim Y. S., Kim D., Flint Beal M., Hwang O., A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. Journal of Neurochemistry 2008 106 1 405 415 10.1111/j.1471-4159.2008.05399.x 2-s2.0-45249115717 (Pubitemid 351840221)
34. Reitz C., van Rooij F. J. A., Soares H. D., de Maat M. P. M., Hofman A., Witteman J. C. M., Breteler M. M. B., Matrix metalloproteinase 3 haplotypes and plasma amyloid beta levels: the Rotterdam study. Neurobiology of Aging 2010 31 4 715 718 10.1016/j.neurobiolaging.2008.05.033 2-s2.0-77049084746
35. Horstmann S., Budig L., Gardner H., Koziol J., Deuschle M., Schilling C., Wagner S., Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. International Psychogeriatrics 2010 22 6 966 972 10.1017/S1041610210000827 2-s2.0-77957321489
36. Mattsson N., Insel P., Nosheny R., Trojanowski J. Q., Shaw L. M., Jack C. R. Jr., Tosun D., Weiner M., Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiology of Aging 2014 35 3 614 622
37. Helbecque N., Cottel D., Hermant X., Amouyel P., Impact of the matrix metalloproteinase MMP-3 on dementia. Neurobiology of Aging 2007 28 8 1215 1220 10.1016/j.neurobiolaging.2006.05.030 2-s2.0-34249322625 (Pubitemid 46810058)
38. Vasto S., Candore G., Duro G., Lio D., Grimaldi M. P., Caruso C., Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision. Pharmacogenomics 2007 8 12 1735 1745 10.2217/14622416.8.12.1735 2-s2.0-37649011164
39. Ito S., Kimura K., Haneda M., Ishida Y., Sawada M., Isobe K., Induction of matrix metalloproteinases (MMP3, MMP12 and MMP13) expression in the microglia by amyloid- β stimulation via the PI3K/Akt pathway. Experimental Gerontology 2007 42 6 532 537 10.1016/j.exger.2006.11.012 2-s2.0-34248592575 (Pubitemid 46756086)
40. Stomrud E., Björkqvist M., Janciauskiene S., Minthon L., Hansson O., Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimer's Research and Therapy 2010 2 3, article 20 10.1186/alzrt44 2-s2.0-77954788631
41. Liao M., van Nostrand W. E., Degradation of soluble and fibrillar amyloid β -protein by matrix metalloproteinase (MT1-MMP) in vitro. Biochemistry 2010 49 6 1127 1136 10.1021/bi901994d 2-s2.0-76749099393
42. Higashi S., Miyazaki K., Identification of amino acid residues of the matrix metalloproteinase-2 essential for its selective inhibition by β -amyloid precursor protein-derived inhibitor. The Journal of Biological Chemistry 2008 283 15 10068 10078 10.1074/jbc.M709509200 2-s2.0-44349092576
43. Brew K., Nagase H., The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochimica et Biophysica Acta-Molecular Cell Research 2010 1803 1 55 71 10.1016/j.bbamcr.2010. 01.003 2-s2.0-77049113770
44. Inspector M., Aharon-Perez J., Glass-Marmor L., Miller A., Matrix metalloproteinase-9, its tissue inhibitor (TIMP)-1 and CRP in Alzheimer's disease. European Neurology 2005 53 3 155 157 10.1159/000086124 2-s2.0-20844434806 (Pubitemid 40864309)
45. Lewczuk P., Popp J., Lelental N., Kölsch H., Maier W., Kornhuber J., Jessen F., Cerebrospinal fluid soluble amyloid- β protein precursor as a potential novel biomarkers of Alzheimer's disease. Journal of Alzheimer's Disease 2012 28 1 119 125 10.3233/JAD-2011-110857 2-s2.0-84855796427
46. Adair J. C., Charlie J., Dencoff J. E., Kaye J. A., Quinn J. F., Camicioli R. M., Stetler-Stevenson W. G., Rosenberg G. A., Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke 2004 35 6 e159 e162 10.1161/01.STR. 0000127420.10990.76 2-s2.0-7944234032